Artus

Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.

Retrieved on: 
Tuesday, January 30, 2024
Patient, LCEA, Partnership, Urinary incontinence, Artus, Euronext Paris, Ticker, Medtech, Shareholder, Medicine, Aix-en-Provence, FDA, Mitral valve, Surgeon, Security (finance)

Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.

Key Points: 
  • Affluent Medical closes €3.5 million bridge via capital increase from key shareholders.
  • Key shareholders provide bridge to continue exploring options to secure long term financing.
  • Aix-en-Provence, 29 January 2024 - 5:45 pm - Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specialising in the international development and industrialisation of innovative medical prostheses, today announced the closing of a €3.5 million bridge financing with its key existing shareholders.
  • Following this transaction, Affluent Medical share capital now consists of 33.145.236 shares, each with a nominal value of €0.10.

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Retrieved on: 
Saturday, December 30, 2023
Neurostimulation, EAU, Woman, Medtech, Research, Male, Hope, Nursing, European, Health, Ageing, Urinary incontinence, Mental health, Anxiety, Incontinence, Prostate, Pathology, Aix-en-Provence, Patient, Ticker, Artus, Disorder, Female, Pharmaceutical industry

Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.

Key Points: 
  • Affluent Medical : Start of the European pilot study with the Artus medical device for the treatment of urinary incontinence.
  • Artus is an innovative device adapted for the treatment of incontinence in women and men.
  • Aix-en-Provence, 6 December 2023 – Affluent Medical (ISIN: FR0013333077 – Ticker: AFME), a French clinical-phase MedTech company specialising in the international development and industrialisation of innovative medical prostheses, is announcing the start of the European pilot study, Dry, with its Artus medical device for the treatment of urinary incontinence.
  • Publication of an international study by the European Association of Urology on the economic consequences of urinary incontinence in Europe.

Affluent Medical : H1 2023 results. Major advances in clinical programs. Extension of cash horizon to February 2024.

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, Regulatory News Service, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Pharmaceutical industry, Medical imaging, Medical device, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • This transcatheter approach avoids an invasive "open heart" procedure and associated complications to treat mitral valve insufficiency.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

EQS-News: Affluent Medical SA: H1 2023 RESULTS - Major advances in clinical programs - Extension of cash horizon to February 2024

Retrieved on: 
Thursday, September 28, 2023
Artus, NYHA, US Foods, Urinary incontinence, Disease, Human, Statutory auditor, Tricuspid valve, Myocardial infarction, DSMB, Butterfly valve, Hospital, Boston Scientific, Bank statement, Abbott, Anatomy, Aortic stenosis, Food, Clinical trial, Optimization, Quality of life, Minerva, MR, Kalio, Doctor of Philosophy, TAVI, New York Heart Association Functional Classification, Medtronic, Mitral regurgitation, MD, Patient, Mitral valve, Risk, Data, CEST, Engineering, ISIN, DSM-IV codes, Neurostimulation, FDA, Death, Aix-en-Provence, III, Medtech, Medical imaging, Medical device, Pharmaceutical industry, Nursing, Fine chemical, Science

Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.

Key Points: 
  • Since early 2023, Affluent Medical has been developing its medical devices and announced important clinical advances in each of its three programs.
  • In March 2023, Affluent Medical announced the successful first implantation of the Epygon biomimetic mitral heart valve in a patient with a severe mitral valve insufficiency profile combined with several comorbidity factors.
  • Affluent Medical believes that Kalios would avoid further intervention for potentially 30-40% of patients over a five-year horizon.
  • This transaction would be intended to finance ongoing clinical programs and could receive the support of its reference shareholders.

Affluent Medical : Affluent Medical announces the major success of its capital increase with preferential subscription rights for about €13.7 million

Retrieved on: 
Thursday, March 2, 2023
Quality of life, Equity carve-out, Minerva, Artus, Exercise, Dry, Patient, Aix-en-Provence, Regulatory News Service, Voltage optimisation, Medtech, ISIN, Pathology, Urinary incontinence, PSR, Parveen Farzana Absar, Security (finance), Medical device, Bpifrance, Euronext Paris

Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "I truly thank all the shareholders, and especially our reference shareholder Truffle Capital, who demonstrated their confidence with their participation to this capital increase that contributed to its great success.

Key Points: 
  • Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "I truly thank all the shareholders, and especially our reference shareholder Truffle Capital, who demonstrated their confidence with their participation to this capital increase that contributed to its great success.
  • The gross amount of the Capital Increase is therefore €13,697,707.50 through the issue of 10,146,450 ABSARs at a unit subscription price of €1.35.
  • The Company’s share capital after the capital increase will total €30,896,652 divided into 30,896,652 shares with a nominal value of €1 each.
  • To the knowledge of the Company, the distribution of capital and voting rights following the Capital Increase is as follows:

Affluent Medical : Affluent Medical announces the launch of a capital increase of around €13 million with preferential subscription rights maintained by shareholders

Retrieved on: 
Monday, February 13, 2023
Ex-dividend date, Minerva, ISIN, Mitral insufficiency, Union, Dry, Aix-en-Provence, BSAR, Prospectus, Urinary incontinence, Person, Equity carve-out, Absar Alam (journalist), Exercise, Patient, Quality of life, Adrenal insufficiency, Voluntary Optimisation of Class Structure Scheme, Commercial code, Parity, Artus, DPS, Nightclub, Security (finance), Medical imaging, Medical device, Bank, Management, Euronext Paris, Bpifrance

Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "Affluent Medical enters 2023 with a clear roadmap and strong ambitions.

Key Points: 
  • Sébastien Ladet, Chief Executive Officer of Affluent Medical, said: "Affluent Medical enters 2023 with a clear roadmap and strong ambitions.
  • The development of accessories for Epygon and the industrialization of medical devices Epygon and Artus would be postponed.
  • Each shareholder of Affluent Medical may subscribe for 13 ABSARs on an irreducible basis for 28 existing shares held, i.e.
  • Preferential subscription rights will be traded on Euronext Paris from February 10, 2023 to February 23, 2023, inclusive, under ISIN code FR001400FL20.

Affluent Medical : Financial results for H1 2022 and significant progresses in 2022.

Retrieved on: 
Wednesday, September 28, 2022
Adrenal insufficiency, IFRS, Safety, Development, ISIN, Statutory auditor, Woman, Minerva, FDA, Degenerative disease, Dry, Company, Medtech, Review, AstraZeneca, Patient, Urinary incontinence, Progress, III, DVM, CE, Medtronic, Research and development, EMEA, General manager, Artus, Financial result, Board, NYHA, UCB, Neurology, Regulatory News Service, Optimization, Marketing, Bristol Myers Squibb, Man, Hospital, Sanofi, Actelion, Mitral valve, Mission statement, Management, Medical imaging, Medical device, Pharmaceutical industry, Research, Director, Hernia, Terumo

Affluent Medical : Financial results for H1 2022 and significant progresses in 2022.

Key Points: 
  • Affluent Medical : Financial results for H1 2022 and significant progresses in 2022.
  • Since the beginning of the year, Affluent Medical has successfully managed new patient recruitment timelines to be able to continue its clinical studies for its three medical devices.
  • On September 20, Affluent Medical announced a successful capital increase through the issue of New Shares with Preferential Subscription Rights maintained.
  • Dr. Giot, who joined Affluent Medical last July, has medical practice experience in hospitals, particularly in the field of vascular diseases.

Affluent Medical : Financial results for the first half of 2021 and main clinical update.

Retrieved on: 
Wednesday, September 22, 2021
ESC, Man, Review, American College of Cardiology, Feedback, FCCP, Death, University, Icahn School of Medicine at Mount Sinai, Silver, Cotignola, Degenerative disease, University of Paris, Mitral valve, FAHA, Heart, Neuro, Group, Education, Committee, Journal, IFRS, Andreas, Cardiovascular disease, Urinary incontinence, EAU, Professor, Company, FESC, Health policy, BJU International, Kalio, Mehran, SAIME, NYHA, The Journal of Urology, Surgeon, COVID-19, Patient, FACC, FACP, American College, Ethics, Adrenal insufficiency, Nature Reviews Urology, Trial of the century, Mount Sinai Hospital, IPO, European Urology, Artus, Animal, Security (finance), Medical device, Pharmaceutical industry, Medicine

During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.

Key Points: 
  • During the first half of 2021, purchases consumed fell by 158 thousand compared to the first half of 2020.
  • On 9 June 2021, Affluent Medical announced the success of its IPO on the regulated market of Euronext Paris.
  • Starting in 2018 he broadened his field of expertise by engaging in various entrepreneurial projects before joining Affluent Medical.
  • Affluent Medical develops innovative, next-generation minimally invasive implants to restore essential physiological functions in these areas.

5 Modern Residences That Preserve and Showcase Artisanship

Retrieved on: 
Friday, April 26, 2019
Luxury, Travel, Destinations, Architecture, Retail, Construction & Property, Commercial Building & Real Estate, Residential Building & Real Estate, K11 ARTUS, Real estate in Hong Kong, K11, Artus

K11 ARTUS will also host year-round salons featuring leading cultural figures, adding an unexpected intellectual component to the facilities, while an experiential space will be carved out to showcase the best of Chinese craft heritage.

Key Points: 
  • K11 ARTUS will also host year-round salons featuring leading cultural figures, adding an unexpected intellectual component to the facilities, while an experiential space will be carved out to showcase the best of Chinese craft heritage.
  • From an architecture perspective, the bulk of the 287 short- and long-stay residences have been designed by Andre Fu, with a jaw-dropping harbour view from its sinuous balconies.
  • Custom commissions include cane seating, block-printed curtains and stunning lampshades made from vintage saris that become the focal point of each room.
  • The result is a curvaceous and architecturally breathtaking home for guests that is entirely replicable in other villages.